Genelux (GNLX) Notes Payables (2022 - 2023)
Genelux (GNLX) posted quarterly Notes Payables of $40000.0 for Q4 2023, down 95.97% year-over-year from $992000.0 in Q4 2022, and little changed quarter-over-quarter from $40000.0 in Q3 2023.
Genelux (GNLX) Notes Payables (2022 - 2023) Analysis & Trends
Genelux's Notes Payables history runs 2 years deep, the most recent figure standing at $40000.0 for Q4 2023.
- In Q4 2023, Notes Payables fell 95.97% year-over-year to $40000.0; the TTM figure through Dec 2023 stood at $40000.0 (down 95.97% YoY), while the FY2023 annual figure was $40000.0, down 95.97% from the prior year.
- Notes Payables for Q4 2023 stood at $40000.0, roughly flat from $40000.0 in the prior quarter.
- The five-year high for Notes Payables was $992000.0 in Q4 2022, with the low at $40000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 40,000.00 |
| Sep 30, 2023 | 40,000.00 |
| Dec 31, 2022 | 992,000.00 |